44 results on '"Gustavson, M."'
Search Results
2. 1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
3. Limits to Wind Power Utilization
4. Evolving Strategic Arms and the Technologist
5. The synovial sarcoma translocation protein SYT-SSX2 recruits β-catenin to the nucleus and associates with it in an active complex
6. 13P HER2 low testing in breast cancer: How to optimize detection
7. Limits to Wind Power Utilization.
8. Non-Air-Breathing Auxiliary Powerplants
9. Abstract P2-05-06: Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite Breast™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)
10. Breast Lobules
11. An eDNA assay for Irish Petromyzon marinus and Salmo trutta and field validation in running water
12. Abstract P4-08-02: A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors
13. Radiation Therapy
14. Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study.
15. Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology
16. Caledonides of north-central Norway
17. Relaxation techniques for fast reactions. A study of the dissociation of nitrogen tetroxide.
18. Toward an energy ethic.
19. Response : Evolving Strategic Arms and the Technologist
20. Ueber den Vierfach-Jodkohlenstoff
21. Time distortion in nuclear war
22. Dimensions of world energy
23. Toward an energy ethic
24. Some thoughts on FRG views/outlook as of August 1988 visit
25. New questions in strategic theory
26. Passport program. Quarterly technical progress summary No. 3 (April--June 1968)
27. Passport program. Quarterly technical progress summary No. 4 (July-- September 1968)
28. Passport program. Quarterly technical progress summary No. 7 (April--June 1969)
29. Passport program quarterly technical progress summary number 8, July-- September 1969
30. Passport program. Quarterly technical progress summary No. 5 (October-- December 1968)
31. Passport program. Quarterly technical progress summary No. 9 (October-- December 1969)
32. HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
33. Subjective Hearing Difficulty and Fall Risk.
34. Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.
35. Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology.
36. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.
37. Company Profile: HistoRx: tissue-based diagnostic solutions for personalized medicine.
38. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
39. Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence.
40. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.
41. Analytic variability in immunohistochemistry biomarker studies.
42. Automated analysis of tissue microarrays.
43. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors.
44. Mapping of two mouse membrane-type matrix metalloproteinase (MT-MMP) genes, Mmp15 and Mmp16, to mouse chromosomes 8 and 4, respectively.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.